New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
11:56 EDTFLMLFDA change on neostigmines could be significant for Flamel, says Summer Street
Summer Street notes that the FDA has changed its drug shortage website and now lists Flamel Technologies' Bloxiverz as the "first and only" approved neostigmine, which the firm thinks may mean that the FDA could be taking action to remove unapproved neostigmines from Fresenius or West-Ward Pharma. Summer Street thinks this change could be a "hugely significant" milestone for Flamel and its Eclat strategy and reiterates its Buy rating and $24.75 price target on the share.
News For FLML From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:56 EDTFLMLFlamel backs FY15 revenue guidance of $170M-$185M, consensus $194.87M
Subscribe for More Information
07:56 EDTFLMLFlamel reports Q2 adjusted EPS 34c, consensus 40c
Subscribe for More Information
July 22, 2015
08:31 EDTFLMLFlamel to begin U.S. public company reporting status in FY16
Flamel announced that as of June 30, it has determined that it no longer satisfies the definition of a "foreign private issuer" under the rules and regulations of the SEC. The company made the determination based on the fact that the proportion of its voting securities currently held by U.S residents is approximately 80% or greater and a majority of its executive officers are U.S. citizens or residents. As a result, beginning on January 1, 2016, the company will be filing Annual Reports on Form 10-K, commencing with the annual report to be filed for the year ended December 31, 2015, Current Reports on Form 8-K, Quarterly Reports on Form 10-Q as well as proxy statements with respect to meetings of shareholders, with the SEC as if it were a fully domestic U.S. company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use